Cretion by monocytes. J Immunol 2013, 191(8):4059?067. 7. Elias JA, Zitnik RJ: PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/20460822 Cytokine-cytokine interactions in the context of cytokine networking. Am J Respir Cell Mol Biol 1992, 7:365?67. 8. Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA: Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 2001, 34:273?82. 9. Catherine O, Jayat-Vignoles C, Magali D, Jean F: Both CD62 and CD162 Antibodies Prevent Formation of CD36-Dependent Platelets, Rosettes, and Artefactual Pseudoexpression of Platelet Markers on White Blood Cells: 3-Amino-1H-indazole-4-carbonitrile A Study with Image Stream. Cytometry A 2011, 79A:477?84. 10. Wynn TA, Hesse M, Sandler NG, Kaviratne M, Hoffmann KF, Chiaramonte MG, Reiman R, Cheever AW, Sypek JP, Mentink-Kane MM: P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon gamma and the IL-13 decoy receptor. Hepatology 2004, 39(3):676?7. 11. Austrup F, Vestweber D, Borges E, L ning M, Br er R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A: P- and E-selectin mediateConclusion The present study highlights the considerable role of P-selectin in the progression of CLD caused by HCV and S.mansoni. By upregulating platelet activation, P-selectin modulates consequences of chronic type 2 cytokine?mediated inflammation. Although selectins frequently are referred to as provocative mediators, it remains indistinct whether this impact results from the direct effect of P-selectin on leukocyte recruitment or it is basically an outcome of the altered host immune reaction. The extent of platelet and lymphocyte activation markers described herein releases PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/3081428 a new gap for prognostics predicting the progression of HCV and schistosomiasis mansoni induced CLD and consequently, the development of new preventive measures.Kamel et al. BMC Gastroenterology 2014, 14:132 http://www.biomedcentral.com/1471-230X/14/Page 8 of12.13.14.15.16.17.18.19.20.21.22.23.24. 25. 26.27.28.29.30.31.recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997, 385:81?3. Balakrishna J, Venkateswarlu S, Kusuma B, Hussain Saheb S: Comparison of modified 1 potassium hydroxide formol-ether concentration technique with direct wet mount preparation and standard formol-ether concentration technique for detection of parasites in stool. J Pharm Sci 2013, 5(7):147?49. Engvall E, Perlman P: ELISA quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen coated tubes. J Immunol 1971, 109:129?35. Guesdon JL, Ternynck T, Avrameas S: The use of avidin biotin interaction in tert-Butyl (7-bromoheptyl)carbamate 24 immune-enzymatic techniques. J Histochem Cytochem 1979, 27:1131?139. Kishirnoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretto L, Ohno T, Okurnura K, Shaw S, Springer TA, Sugarnura K, Sugawara H, Borne AEG Kr V d, Zola H: Update of CD antigens. J Immunol 1997, 158:3035?036. Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J: Activation of blood platelets in chronic hepatitis and liver cirrhosis p-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and p1q2'elet factor-4. Hepatogastroenterology 2001, 48:818?22. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL: HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659?62. Schirren CA, Jung MC, Worzfeld T, Mamin M, Baretton G, Gerlach JT: Hepatitis C virus-specific CD4+ T cell response after liver.